MedTrace Logo

Effect of Fecal Capsule on Chronic Kidney Disease (CKD)

NCT06166667 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-05-16

No results posted yet for this study

Summary

By collecting blood, urine and stool samples before and after oral Enterobacteriaceae capsule (FMT) from CKD subjects, we investigated the role and related mechanisms of gut microecology in the development of CKD using a combination of metagenomic sequencing, metabolomic analysis and flow cytometry.

Conditions

  • Renal Insufficiency, Chronic

Interventions

PROCEDURE

Fecal Microbiota Transplant（FMT）

Patients involved in the trial received 20 capsules of Enterobacteriaceae (one course) on days 1, 8, and 15, which were provided by Dongyuan Yikang company. Patients were prohibited from taking antibiotics such as amoxicillin and Cefalexin during the trial.

Sponsors & Collaborators

  • Shanxi Provincial People's Hospital

    lead OTHER_GOV

Principal Investigators

  • Yafeng Li, Professor · Shanxi Provincial People's Hospital (Fifth Hospital) of Shanxi Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06166667 on ClinicalTrials.gov